https://www.selleckchem.com/GSK-3.html
Potassium-competitive acid blockers (P-CABs) are emerging as novel treatments for acid-related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan are approved P-CABs in South Korea, but the pharmacodynamics and safety/tolerability of the two drugs have never been compared. To evaluate the pharmacodynamics and safety/tolerability of tegoprazan and revaprazan after single and multiple oral doses METHODS A randomised, open-label, active-controlled study was conducted in Helicobacter pylori-negative healthy Korean male subj
Me gusta
Comentario
Compartir
